These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 22258468)

  • 1. (Q)SAR modeling and safety assessment in regulatory review.
    Kruhlak NL; Benz RD; Zhou H; Colatsky TJ
    Clin Pharmacol Ther; 2012 Mar; 91(3):529-34. PubMed ID: 22258468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk management frameworks for human health and environmental risks.
    Jardine C; Hrudey S; Shortreed J; Craig L; Krewski D; Furgal C; McColl S
    J Toxicol Environ Health B Crit Rev; 2003; 6(6):569-720. PubMed ID: 14698953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of rodent carcinogenic potential of naturally occurring chemicals in the human diet using high-throughput QSAR predictive modeling.
    Valerio LG; Arvidson KB; Chanderbhan RF; Contrera JF
    Toxicol Appl Pharmacol; 2007 Jul; 222(1):1-16. PubMed ID: 17482223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improving the decision-making process in structural modification of drug candidates: reducing toxicity.
    Nassar AE; Kamel AM; Clarimont C
    Drug Discov Today; 2004 Dec; 9(24):1055-64. PubMed ID: 15582794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Promises and pitfalls of quantitative structure-activity relationship approaches for predicting metabolism and toxicity.
    Zvinavashe E; Murk AJ; Rietjens IM
    Chem Res Toxicol; 2008 Dec; 21(12):2229-36. PubMed ID: 19548346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Researches on the in silico prediction of structure-activity relationship in the regulatory science sectors].
    Hirose A
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2010; (128):27-8. PubMed ID: 21381391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. On the number of EINECS compounds that can be covered by (Q)SAR models for acute toxicity.
    Zvinavashe E; Murk AJ; Rietjens IM
    Toxicol Lett; 2009 Jan; 184(1):67-72. PubMed ID: 19041378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early communication of drug safety concerns: a feasibility study on enhancing interaction between the pharmaceutical industry and regulators.
    Swain E; Morgan S; Brewster W; Kauser S
    Pharmacoepidemiol Drug Saf; 2010 Mar; 19(3):232-7. PubMed ID: 20033909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. (Q)SAR: A Tool for the Toxicologist.
    Steinbach T; Gad-McDonald S; Kruhlak N; Powley M; Greene N
    Int J Toxicol; 2015; 34(4):352-4. PubMed ID: 25979517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Capability maturity models for offshore organisational management.
    Strutt JE; Sharp JV; Terry E; Miles R
    Environ Int; 2006 Dec; 32(8):1094-105. PubMed ID: 17049602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Secondary use of randomized controlled trials to evaluate drug safety: a review of methodological considerations.
    Hammad TA; Pinheiro SP; Neyarapally GA
    Clin Trials; 2011 Oct; 8(5):559-70. PubMed ID: 21878445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of advances in technology for maritime risk assessment.
    Wang J; Sii HS; Yang JB; Pillay A; Yu D; Liu J; Maistralis E; A Saajedi
    Risk Anal; 2004 Aug; 24(4):1041-63. PubMed ID: 15357827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of the European Chemicals Bureau in promoting the regulatory use of (Q)SAR methods.
    Worth AP; Bassan A; De Bruijn J; Gallegos Saliner A; Netzeva T; Patlewicz G; Pavan M; Tsakovska I; Eisenreich S
    SAR QSAR Environ Res; 2007; 18(1-2):111-25. PubMed ID: 17365963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular clinical safety intelligence: a system for bridging clinically focused safety knowledge to early-stage drug discovery - the GSK experience.
    Vanderwall DE; Yuen N; Al-Ansari M; Bailey J; Fram D; Green DV; Pickett S; Vitulli G; Luengo JI; Almenoff JS
    Drug Discov Today; 2011 Aug; 16(15-16):646-53. PubMed ID: 21601652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of the European centre for the validation of alternative methods (ECVAM) in the validation of (Q)SARs.
    Worth AP; Hartung T; Van Leeuwen CJ
    SAR QSAR Environ Res; 2004; 15(5-6):345-58. PubMed ID: 15669694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioaccumulation assessment using predictive approaches.
    Nichols JW; Bonnell M; Dimitrov SD; Escher BI; Han X; Kramer NI
    Integr Environ Assess Manag; 2009 Oct; 5(4):577-97. PubMed ID: 19775192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative analysis of pharmaceuticals versus industrial chemicals acute aquatic toxicity classification according to the United Nations classification system for chemicals. Assessment of the (Q)SAR predictability of pharmaceuticals acute aquatic toxicity and their predominant acute toxic mode-of-action.
    Sanderson H; Thomsen M
    Toxicol Lett; 2009 Jun; 187(2):84-93. PubMed ID: 19429249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Signal detection in post-marketing surveillance for controlled substances.
    Dasgupta N; Schnoll SH
    Drug Alcohol Depend; 2009 Dec; 105 Suppl 1():S33-41. PubMed ID: 19616902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A framework for joint modeling and joint assessment of efficacy and safety endpoints for probability of success evaluation and optimal dose selection.
    He W; Cao X; Xu L
    Stat Med; 2012 Feb; 31(5):401-19. PubMed ID: 22161805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of physiologically based pharmacokinetic modeling in regulatory review.
    Huang SM; Rowland M
    Clin Pharmacol Ther; 2012 Mar; 91(3):542-9. PubMed ID: 22318616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.